#United States #Irvine #Nuravax #AV-1959R #Amyloid-Beta Vaccine

Nuravax and Institute for Molecular Medicine Announce Phase 1 Results for AV-1959R Amyloid-Beta Vaccine

On October 13, 2026, Nuravax, Inc. in collaboration with the Institute for Molecular Medicine (IMM), published the results of their Phase 1 clinical trial for AV-1959R, an investigational vaccine targeting amyloid-beta (Aβ), a protein commonly associated with Alzheimer's disease. The trial, a randomized, double-blind, placebo-controlled study, included 16 cognitively unimpaired participants, with 12 receiving the AV-1959R vaccine and four receiving a placebo.

Key Findings of the Phase 1 Trial

The study successfully met its primary objectives of safety and immunogenicity. All 12 participants who received the vaccine developed anti-Aβ antibody responses after two doses, administered one month apart. The geometric mean titers (GMTs) of antibodies for those receiving 100 µg and 300 µg doses were reported at 60,240 and 69,530 respectively. In contrast, the placebo group did not exhibit any measurable responses, maintaining baseline levels with an average GMT of only 156.

Exploratory analyses demonstrated that the vaccine elicited antibody binding to aggregated forms of Aβ, including protofibrils and fibrils, while showing weaker affinity for oligomers and almost none for monomeric Aβ. Furthermore, serum from vaccinated participants displayed the capacity to bind to amyloid plaques present in the cortical tissue of Alzheimer's patients, though not in control tissues without the disease.

Modeling of antibody kinetics projected that antibody levels could remain fivefold higher than baseline for up to a year after administration, suggesting a potential framework for annual booster vaccinations in future clinical studies. However, the durability of the immune response and its clinical relevance await further investigation.

Insight from Experts

Dr. Michael Agadjanyan, head of Molecular Immunology at IMM and co-founder of Nuravax, emphasized the significance of these results, stating, "Amyloid-beta is a self-protein, making it challenging to generate a robust immune response against its pathological forms. The Phase 1 results provide clinical evidence supporting that our MultiTEP-based vaccine can trigger immunity that preferentially targets aggregated Aβ."

These promising findings lay the groundwork for Nuravax and IMM's forthcoming Phase 2 trial, which aims to include cognitively unimpaired individuals with biomarker-verified amyloid pathology. This trial will not only continue to assess safety but also explore surrogate efficacy through monitoring amyloid and tau-related brain and blood biomarkers.

Future Directions

Despite the encouraging immunogenicity data, the Phase 1 study's small size and design do not allow for conclusions about the vaccine's safety or clinical efficacy. Professor Lon S. Schneider, a key co-author of the study and professor at the Keck School of Medicine, remarked, "While this study provides an initial overview of safety and immunogenicity, the Phase 2 trial is critical for answering these complex questions."

AV-1959R, which is specifically engineered for individuals exhibiting amyloid pathology, remains investigational and has not been approved for any clinical application. The trials are dynamically ongoing, as understanding the immunogenicity and safety profiles of such vaccines can pave the way toward mitigating Alzheimer’s disease in at-risk populations.

Conclusion

The results from Nuravax and IMM herald a significant advance in the quest for an effective preventive vaccine against Alzheimer's disease. With a Phase 2 trial on the horizon, the scientific community waits in anticipation of further developments in harnessing immune responses to combat neurodegenerative diseases. This innovative approach could redefine preventive strategies in Alzheimer’s treatment, potentially changing the course of the disease for future generations.